These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. High-density lipoprotein: structural and functional changes under uremic conditions and the therapeutic consequences. Schuchardt M; Tölle M; van der Giet M Handb Exp Pharmacol; 2015; 224():423-53. PubMed ID: 25522997 [TBL] [Abstract][Full Text] [Related]
6. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia]. Bajnok L Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322 [TBL] [Abstract][Full Text] [Related]
7. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Chapman MJ; Le Goff W; Guerin M; Kontush A Eur Heart J; 2010 Jan; 31(2):149-64. PubMed ID: 19825813 [TBL] [Abstract][Full Text] [Related]
8. Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease. Streja E; Streja DA; Soohoo M; Kleine CE; Hsiung JT; Park C; Moradi H Semin Nephrol; 2018 Jul; 38(4):369-382. PubMed ID: 30082057 [TBL] [Abstract][Full Text] [Related]
9. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582 [TBL] [Abstract][Full Text] [Related]
10. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Agrawal S; Zaritsky JJ; Fornoni A; Smoyer WE Nat Rev Nephrol; 2018 Jan; 14(1):57-70. PubMed ID: 29176657 [TBL] [Abstract][Full Text] [Related]
11. Reverse cholesterol transport in type 2 diabetes mellitus. Tan KC Diabetes Obes Metab; 2009 Jun; 11(6):534-43. PubMed ID: 19175378 [TBL] [Abstract][Full Text] [Related]
12. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Yvan-Charvet L; Kling J; Pagler T; Li H; Hubbard B; Fisher T; Sparrow CP; Taggart AK; Tall AR Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1430-8. PubMed ID: 20448206 [TBL] [Abstract][Full Text] [Related]
13. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus. Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582 [TBL] [Abstract][Full Text] [Related]
15. [Treatment of dyslipidemia: how and when to combine lipid lowering drugs]. Schulz I Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):344-59. PubMed ID: 16767301 [TBL] [Abstract][Full Text] [Related]
19. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
20. Is raising HDL a futile strategy for atheroprotection? Joy T; Hegele RA Nat Rev Drug Discov; 2008 Feb; 7(2):143-55. PubMed ID: 18239670 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]